BridgeBio Oncology Therapeutics files prospectus supplement for resale of 63.1M shares by selling securityholders

Filed August 12, 2026 · ~1 min read

Key Changes

• high

  The prospectus supplement covers the resale of 63,054,549 shares of common stock by selling securityholders; the company will not receive any proceeds from these sales.

  The Offering verify on EDGAR →
• high

  The shares are already outstanding and are being registered for resale; this is a secondary offering, not a primary capital raise.

  The Offering verify on EDGAR →
• medium

  On August 11, 2026, the closing price of the company's common stock on Nasdaq was $9.20 per share.

  The Offering verify on EDGAR →